65,437 trials
Headache · Migraine
Primary: The Primary Outcome Will be Pain Relief Sufficient for Discharge From the Emergency Department. — 16; 14; 2 Participants
Healthy Volunteers
Primary: Maximum Level of Sedation for Lorazepam 1 mg IM + ADASUVE 10 mg — 12.3 units on a scale
Glioblastoma Multiforme of Brain
Primary: Number of Participants With Objective Response — 2; 1; 2; 27 Participants
Abdominal Pain · Pelvic Pain
Primary: Median Fill-To-Done (FTD) Time — 87.5; 139 minutes
Collapsing Glomerulopathy · Glomerulosclerosis, Focal Segmental
Primary: Change in Proteinuria at Week 24 From Baseline — 8.42; 7.67 g/g
Multiple Myeloma · Non-Hodgkin Lymphoma · Hodgkin Disease
Primary: Proportion of Patients From Whom a Total Number of CD34+ Cells ≥5.0 x 10^6 Cells/kg Was Collected Within the First 4 Leukapheresis Sessions — 0.50000; 0.9167; 0.9167…
Glioblastoma Multiforme of the Brain
Primary: Number of Participants With Objective Response — 1; 1; 5; 19 Participants
Actinic Keratosis
Primary: Complete Clearance Rate — 16; 15; 10; 12 AK Fields
Non Small Cell Lung Cancer
Primary: Progression Free Survival at 3 Months — 50.4 percentage of participants
Chronic Plantar Fasciitis
Primary: Average Percentage of Change as Reported Using Foot Function Index Pain Subscale — -54; -25 percentage of Change
Adenocarcinoma of the Gastroesophageal Junction · Esophageal Undifferentiated Carcinoma · Gastric Adenocarcinoma
Primary: Overall Response Rate — 26 percentage of participants
Newly Diagnosed Hormone Positive Clinical Stage 1 or 2 Breast Cancer
Primary: Change in Ki67 Expression in Tumors — -40 percentage change in Ki67 — p=0.0001
Breast Cancer
Primary: Morbidity - Number of Participants With Residual Shoulder Abduction Deficit — 276; 200 Participants
Inadequate Bone Height in Maxillary Posterior Area
Primary: The Percentage of Vital Bone in a Total Amount of a Bone Specimen — 10.9; 9.1; 32.0 percentage of vital bone
Aortic Valve Stenosis · Aortic Valve Stenosis With Insufficiency · Regurgitation, Aortic Valve
Primary: Number of Late Adverse Events Divided by Late Patient Years (Expressed as a Percentage) for the INTUTY Valve Implanted Cohort — 3.9; 0.9; 0.6; 0.3 Percentage of…